Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice

by Selma Atalay, Lara S. van der Schoot, Laura Vandermaesen, Lieke J. van Vugt, Mascha Eilander, Juul M.P.A. van den Reek, Elke M.G.J. de Jong
Published 2021-05-01

Beliefs About Medicines in Patients with Psoriasis Treated with Methotrexate or Biologics: A Cross-sectional Survey Study

by Marisol E. Otero, Juul M.P.A. van den Reek, Peter C.M. van de Kerkhof, Jorre S. Mertens, Marieke M.B. Seyger, Wietske Kievit, Elke M.G.J. de Jong
Published 2019-01-01

Clinical, laboratory, and genetic markers for the development or presence of psoriatic arthritis in psoriasis patients: a systematic review

by Michelle L. M. Mulder, Tamara W. van Hal, Mark H. Wenink, Hans J. P. M. Koenen, Frank H. J. van den Hoogen, Elke M. G. J. de Jong, Juul M. P. A. van den Reek, Johanna E. Vriezekolk
Published 2021-06-01

Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analys...

by Selma Atalay, Juul M.P.A. van den Reek, Marisol E. Otero, Marcellus D. Njoo, Johannes M. Mommers, Paul M. Ossenkoppele, Marjolein I. Koetsier, Maartje M. Berends, Peter C.M. van de Kerkhof, Hans M.M. Groenewoud, Alfons A. den Broeder, Elke M.G.J. de Jong, Wietske Kievit
Published 2020-12-01

Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study

by Juul M.P.A. van den Reek, Lieke J. van Vugt, Martijn B.A. van Doorn, Gayle E. van der Kraaij, Wim J.A. de Kort, Georges P.H. Lucker, Barbara Horvath, M. David Njoo, H. Jorn Bovenschen, Paul M. Ossenkoppele, Marjolein S. De Bruin-Weller, Marjan de Groot, Roland Mommers, Ruud L.M.A. Prevoo, Peter C.M. van de Kerkhof, Phyllis I. Spuls, Wietske Kievit, Elke M.G.J. de Jong
Published 2018-04-01